In this study, the TKI gefitinib was used for long-term treatment of mice with EGFRL858R- and EGFRL858R*Tp53+/−-induced lung cancer to induce drug resistance and then study the mutation burden and gene expression profile. Here, TP53 is linked to lung cancer.